N. Aggarwal

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin

H. Rodbard, J. Seufert, M. Pfeifer, 2016, Diabetes, obesity & metabolism.

Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes

W. S. Denney, G. Paragh, D. Páll, 2015, Diabetes, obesity & metabolism.

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

J. Rosenstock, G. Capuano, K. Usiskin, 2012, Diabetes Care.

One‐year efficacy and safety of saxagliptin add‐on in patients receiving dapagliflozin and metformin

S. Matthaei, N. Iqbal, P. García-Hernández, 2016, Diabetes, obesity & metabolism.

Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers

Lawrence A Leiter, I. Hramiak, H. Gerstein, 2022, Diabetes Therapy.

Metformin extended‐release versus immediate‐release: An international, randomized, double‐blind, head‐to‐head trial in pharmacotherapy‐naïve patients with type 2 diabetes

C. Mathieu, A. Pfeiffer, E. Montanya, 2017, Diabetes, obesity & metabolism.